A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors

Category Primary study
JournalJournal of Clinical Oncology
Year 2011
This article has no abstract
Epistemonikos ID: 6896ffa25a807c3a29615213a0e3f8892e9ca3bd
First added on: Feb 04, 2025